Goldman Sachs upgraded Beta Bionics (BBNX) to Buy from Neutral with a price target of $26, up from $18, which offers 31% upside. The firm’s analysis of the diabetes technology market shows sustained growth and profitability for Beta. The company should experience the most upside within the renewal segment of the market, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX: